INTRODUCTION AND OBJECTIVES: Metabolomics offers the ability to exploit the unique metabolic dysregulation inherent in known pathways of renal cell carcinoma pathogenesis to help guide clinical management. While metabolomic pathways and signatures have been studied of a variety of cancers, the signature of urine of patients with RCC has not been well established. We consequently interrogated distinct urinary pathway-level metabolic shifts in patients following surgical excision of renal masses to differentiate metabolic profiles of highrisk clear cell RCC (ccRCC) from indolent and benign tumors.
INTRODUCTION AND OBJECTIVES: Metabolomics offers the ability to exploit the unique metabolic dysregulation inherent in known pathways of renal cell carcinoma pathogenesis to help guide clinical management. While metabolomic pathways and signatures have been studied of a variety of cancers, the signature of urine of patients with RCC has not been well established. We consequently interrogated distinct urinary pathway-level metabolic shifts in patients following surgical excision of renal masses to differentiate metabolic profiles of highrisk clear cell RCC (ccRCC) from indolent and benign tumors.
METHODS: Patients undergoing surgery for non-metastatic RCC were enrolled in an IRB-approved, institutional biorepository and donated urine samples prior to surgery. Patients 0 pathology was indexed as high-risk (HR), defined as high-grade (Grade III-IV) and/or locally-advanced (pT3 or higher) ccRCC; indolent, defined as pT1-T2 and low-grade (Grade I-II) ccRCC; or benign. Capillary electrophoresis mass spectrometry was utilized to process urine samples in a highthroughput fashion to identify distinctive metabolomic profiles indicative of the three pathologies. Sixty-nine targeted metabolites were detected and quantified; principal components analysis and heatmaps were generated. Differences were analyzed using Welch 0 s t-test. RESULTS: A total of 66 urine specimens were included in our analysis: 30 (45.4%) were from patients with HR RCC, 19 (28.8%) from patients with indolent disease, and 17 (25.8%) from patients with benign pathology. Patients with indolent lesions had higher concentrations of the following unique amino acids compared to benign lesions (p<0.01): Phe (þ42.4%), Tyr (þ52.2%), Trp (þ42.7%) and Lys (þ66%). Concentrations of several unique metabolites differed between benign and HR RCC lesions (p<0.01): Hypoxanthine (-42%), Threonic Acid (þ26%), EAP (þ133%), and Glycerol-3-phosphate (þ110%). HR RCC had smaller concentrations of the following metabolites versus indolent lesions (p<0.01): Betaine (-63%), Hydrouracil (-36%), N-Ac Gln (-56%), Histidine (-42%), and 2-aminoisobutyrate (-47%).
CONCLUSIONS: Given the prevalent metabolic rearrangements in RCC, use of urinary metabolomics represents a promising biomarker that can not only distinguish ccRCC from benign tumors, but also risk-stratify dangerous cancers from indolent ones by identifying specific metabolic profiles. Yoshiyuki Yamamoto*, Motohide Uemura, Kosuke Nakano, Yujiro Hayashi, Cong Wang, Yu Ishizuya, Kyosuke Matsuzaki, Takuji Hayashi, Toshiro Kinouchi, Kentaro Jingushi, Taigo Kato, Atsunari Kawashima, Takeshi Ujike, Akira Nagahara, Kazutoshi Fujita, Ryoichi Imamura, Norio Nonomura, Suita City, Japan INTRODUCTION AND OBJECTIVES: Reliable biomarkers for renal cell carcinoma (RCC) have yet to be found. Recently, circulating cell-free DNA (cfDNA) is getting more attention as an emerging biomarker for several types of cancer. The aim of this study is deciphering the characteristics of cfDNA in RCC patients as novel blood biomarkers.
METHODS: Plasma cfDNA was extracted from RCC patients (n ¼ 92) and healthy controls (n ¼ 41). Absolute copy number of cfDNA was determined using quantitative real-time PCR of ACTB as the target gene. We also measured the fragment size of cfDNA using a microfluidics-based platform. Diagnostic capability of these markers was assessed using receiver operating characteristic (ROC) and logistic regression analysis. Log rank test was used for comparison of prognosis between patients having shorter ( 166 bp) or longer (>166 bp) fragment size of cfDNA.
RESULTS: Mean absolute copy numbers of cfDNA in RCC patients were significantly higher than those in healthy controls (5176 vs 2584 copies/ml, p < 0.001). Mean fragment sizes of cfDNA in RCC patients were shorter than those in healthy controls (168.4 vs 171.4 bp, p ¼ 0.052). ROC curve analysis revealed that absolute copy number of cfDNA had a sensitivity of 63.0% and a specificity of 78.1% for the presence of RCC (area under the curve ¼ 0.762, p < 0.001). Multivariate analysis indicated that age, gender and absolute copy number of cfDNA were significantly associated with the presence of RCC (p < 0.001, p ¼ 0.013, p < 0.001, respectively). We further investigated whether the fragment size of cfDNA was correlated with the prognosis of RCC patients. Interestingly, as shown in figure below, the "short fragment size" group had significantly worse progression-free survival compared with "long fragment size" group (p ¼ 0.006). In "short fragment size" group, the fragment size of cfDNA became significantly longer in postoperative states (p ¼ 0.020).
CONCLUSIONS: Our study revealed that the absolute copy number of cfDNA could be the reliable marker for the diagnosis of RCC, and that the fragment size of cfDNA might affect the prognosis of RCC patients. Our findings suggest that sequential measurement of these potential biomarkers lead to better understanding of RCC progression.
Source of Funding: This work was supported by a KAKENHI grant (16K20139).

MP88-05 CLINICAL SIGNIFICANCE OF PHENOTYPING AND KARYOTYPING OF DETECTING CIRCULATING TUMOR CELLS IN RENAL CELL CARCINOMA USING SUBTRACTION ENRICHMENT AND IMMUNOSTAINING-FLUORESCENCE IN SITU HYBRIDIZATION (SET-IFISH)
Mingxin Zhang*, Hanzhong Li, Yushi Zhang, Beijing, China, People's Republic of INTRODUCTION AND OBJECTIVES: Circulating tumor cells (CTCs) have emerged as promising tools for noninvasive cancer detection and prognosis. Most conventional approaches for capturing CTCs use an EpCAM-based enrichment strategy, which does not work well in cancers that show low or no expression of EpCAM, such as renal cell carcinoma (RCC). Karyotyping and phenotyping of circulating tumor cells (CTCs) in therapeutic cancer patients is of particular clinical significance in terms of both identifying CTC subtypes and understanding CTC evolution.
METHODS: The integrated subtraction enrichment (SET) and immunostaining-fluorescence in situ hybridization (iFISH) platform was applied to detect and characterize CTCs in patients with renal cell carcinoma (RCC). Status of vimentin expressing and aneuploidy of chromosome 8 in CTCs enriched from the patients was examined by SET-iFISH following VEGF-targeted therapy. CellSearch system was applied as a reference control.
RESULTS: Non-hematopoietic CTCs with heteroploid chromosome 8 were detected in 82% of RCC patients. Characterization of CTCs performed by vimentin-iFISH was strong positive in 50% of renal CTCs, Phenotyping of CTCs in vimentin positive RCC patients demonstrated that vimentinþ CTCs could be associated with disease progression, including pathologic features and clinical staging. Karyotyping of CTCs indicated that distinct CTCs with different ploidies of chromosomes 8 in RCC patients correlated to either sensitivity or resistance of VEGF-targeted therapy. Examination of the copy number of chromosome 8 in CTCs provides a potential approach for predicting efficacy and monitoring resistance of VEGF-targeted therapy.
CONCLUSIONS: Phenotyping and karyotyping of the enriched CTCs upon ploidy of chromosome 8 or vimentin expression is of clinical potential for monitoring resistance and evaluating therapeutic efficacy for RCC patients.
Source of Funding: none
MP88-06 EXPLORATION OF BIOMARKERS ASSOCIATED WITH PROGNOSIS IN PATIENTS WITH CLEAR CELL RENAL CELL CARCINOMA UNDERGOING SURGICAL RESECTION BY DESORPTION ELECTROSPRAY IONIZATION IMAGING MASS SPECTROMETRY
Keita Tamura*, Makoto Horikawa, Takayuki Sugiyama, Hideaki Miyake, Mitsutoshi Setou, Hamamatsu, Japan INTRODUCTION AND OBJECTIVES: Proteome analysis has become one of the major approaches for the investigation of biomarkers predicting the prognosis of various types of malignant tumor, while metabolome analysis has recently been introduced in this field as the novel promising approach. Despite being widely spread for the screening of small biomolecules, conventional mass spectrometry (MS) analysis using tissue lysate cannot clearly distinguish between the cancerous and non-cancerous tissues; thus, there is a risk for obtaining false positive candidates. In this study, we applied desorption electrospray ionization imaging mass spectrometry (DESI-IMS), a novel molecular anatomy technique, to analyze a broad range of lipids in specimens from patients with clear cell renal cell carcinoma (CCRCC) to identify biomarkers that can predict the prognosis in these patients.
METHODS: Paired samples of the cancerous and normal renal cortex tissues were obtained from a total of 31 patients with CCRCC undergoing surgical resection. The DESI-IMS analyses of thinly sectioned samples were performed in negative ion mode with Xevo G2-XS (Waters, US). We picked up the ions showing 1.5 times higher signal intensity on the cancerous tissue compared with the normal tissue using High Definition Imaging software, and identified the molecules with LIPID MAPS database. We also analyzed the impact of candidate molecules on the overall survival (OS) in these 31 CCRCC patients.
RESULTS: The ions of m/z 187.10 (azelaic acid), m/z 279.23 (linoleic acid), m/z 281.25 (oleic acid), m/z 329.25 (docosapentaenoic acid), m/z 389.24 (not assigned), m/z 391.26 (not assigned), m/z 773.53 (PG (36:2)) were identified as the candidate biomarkers. Of these biomarkers, the low signal intensity of oleic acid as well as the high signal intensity of m/z 391.26 appeared to be significantly associated with the OS in the 31 patients with CCRCC.
CONCLUSIONS: In this study, we first identified seven lipid molecules specifically elevated on the cancerous tissue of CCRCC, and found the significant impacts of the signal intensities of oleic acid and m/ z 391.26 on the prognosis of CCRCC patients undergoing surgical resection. Although future prospective study with a larger sample size will be required, these findings provide new insights for early diagnosis and prognostic prediction in patients with CCRCC.
